INAB (IN8bio) Other Stockholders Equity : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is IN8bio Other Stockholders Equity?

IN8bio's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $0.00 Mil.

IN8bio's quarterly Other Stockholders Equity increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) but then stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).

IN8bio's annual Other Stockholders Equity declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) and declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

IN8bio Other Stockholders Equity Historical Data

The historical data trend for IN8bio's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio Other Stockholders Equity Chart

IN8bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

IN8bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

IN8bio Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

IN8bio Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of IN8bio's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IN8bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

6JH:Germany

Address

350 5th Avenue, Suite 5330, New York, NY, USA, 10118

Website

https://www.in8bio.com

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Executives

Jeremy R. Graff	director	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall	officer: Chief Financial Officer	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho	director, officer: President, CEO and CFO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l.	director, 10 percent owner	40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc	10 percent owner	10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb	officer: EVP and CSO	C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp	director, 10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami	officer: Chief Medical Officer	C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin	officer: Chief Operating Officer	IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118